These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17896108)

  • 1. Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
    Fürstenberger G; Schmid P; Duquesne A; Ammann M; Senn HJ
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):347-8. PubMed ID: 17896108
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
    Medley L; Morel AN; Farrugia D; Reed N; Hayward N; Davies JM; Kirichek O; Thakker RV; Talbot DC
    Br J Cancer; 2011 Mar; 104(7):1067-70. PubMed ID: 21386841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours.
    Krzyzanowska MK; Tsao MS; Oza AM; Haider M; Feld R; Knox J; Chin S; Hu H; Siu LL
    Clin Oncol (R Coll Radiol); 2006 Feb; 18(1):88-9. PubMed ID: 16477931
    [No Abstract]   [Full Text] [Related]  

  • 4. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
    van Essen M; Krenning EP; Kam BL; de Herder WW; van Aken MO; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):743-8. PubMed ID: 18188559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of capecitabine in refractory metastatic medullary thyroid carcinoma.
    Paiva CE; Michelin OC
    Thyroid; 2008 May; 18(5):587. PubMed ID: 18466083
    [No Abstract]   [Full Text] [Related]  

  • 6. Recrudescent meibomian gland carcinoma treated with Xeloda: case report.
    Liang YC; Zhang T; Chen S; Yu DD; Wu HG
    Eur J Ophthalmol; 2014; 24(2):279-81. PubMed ID: 24170512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
    Bajetta E; Catena L; Procopio G; De Dosso S; Bichisao E; Ferrari L; Martinetti A; Platania M; Verzoni E; Formisano B; Bajetta R
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):637-42. PubMed ID: 16937105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine monotherapy in metastatic colorectal cancer.
    Twelves C; Hargreaves D; Nguyen-Van-Tam J; Ng T
    Lancet Oncol; 2001 Jul; 2(7):400. PubMed ID: 11905733
    [No Abstract]   [Full Text] [Related]  

  • 9. Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
    Saadati H; Saif MW
    JOP; 2008 May; 9(3):354-6. PubMed ID: 18469454
    [No Abstract]   [Full Text] [Related]  

  • 10. Granulomatous septal panniculitis associated with capecitabine (Xeloda).
    Dalmau J; Roé E; Puig L; Alomar A
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):121-2. PubMed ID: 18181993
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment.
    Lerner A; Beckford A; Ugent S; Goldberg L; Jalisi S; Demierre MF
    Arch Dermatol; 2011 Aug; 147(8):998-9. PubMed ID: 21844475
    [No Abstract]   [Full Text] [Related]  

  • 12. Pancreatic neuroendocrine tumors: does chemotherapy work?
    Tejani MA; Saif MW
    JOP; 2014 Mar; 15(2):132-4. PubMed ID: 24618436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
    Arvold ND; Willett CG; Fernandez-del Castillo C; Ryan DP; Ferrone CR; Clark JW; Blaszkowsky LS; Deshpande V; Niemierko A; Allen JN; Kwak EL; Wadlow RC; Zhu AX; Warshaw AL; Hong TS
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e337-43. PubMed ID: 22414286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
    Costa FP; Gumz B; Pasche B
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):843-54. PubMed ID: 23582923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
    Vakhabova JV; Semenov NN; Dobrova NV; Lichinitser MR
    Bull Exp Biol Med; 2008 Feb; 145(2):249-51. PubMed ID: 19023981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy.
    Fernandes NF; Rosenbach M; Elenitsas R; Kist JM
    Arch Dermatol; 2009 Mar; 145(3):340-1. PubMed ID: 19289781
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of capecitabine use in patients with liver dysfunction.
    Saif MW; Tejani MA
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):730-2; discussion 736. PubMed ID: 17982413
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
    Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
    Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medullary thyroid cancer treated by capecitabine.
    Labidi SI; Gravis G; Tarpin C; Brun V; Viens P
    Anticancer Drugs; 2007 Aug; 18(7):831-4. PubMed ID: 17581307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of xeloda (capecitabine) in the treatment of cancer patients (review)].
    Orel NF
    Ter Arkh; 2003; 75(10):65-70. PubMed ID: 14669610
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.